Posted on Tuesday, 14th September 2010 by Jesse Walker
SAN FRANCISCO — Forest Laboratories Inc. said Wednesday it finalized an agreement to pay $313 million to resolve improper marketing activities. Forest said the charges are covered by cash reserves and will not affect earnings. Under a deal, Forest’s pharmaceutical unit agreed to plead guilty to one felony count of obstructing a Food and Drug Administration proceeding during an inspection, and two misdemeanor counts involving improper distribution and marketing of medications.
Similar Posts:
- Obama Suggests US Should Be Able To Negotiate Drug Prices
- Pharmaxis sold off after FDA rebuff
- JPMorgan settles muni bid-rigging case for $211 million
- Hits Vs Visitors – Website Traffic Monitoring
- Sun Pharmaceuticals Offers To Buy Out Minority Shareholders In Unit Caraco Pharma
Tags: Marketing, Marketing Probe
Posted in Business Investing | Comments (0)